

Original-Titel:

Variability in adenoma detection rate in control groups of randomized colonoscopy trials: a systematic review and meta-analysis

Autoren:

Cesare Hassan, MD, PhD,1,2,* Daniele Piovani, PhD,1,2,* Marco Spadaccini, MD,1,2,* Tommaso Parigi, MD,1,2, Kareem Khalaf, HBSc, MD,1 Antonio Facciorusso, MD, PhD,3 Alessandro Fugazza, MD,1 Thomas Rösch, MD,4, Michael Bretthauer, MD,5 Yuichi Mori, MD, PhD,5,6 Prateek Sharma, MD,7 Douglas K. Rex, MD,8, Stefanos Bonovas, MD,1,2 Alessandro Repici, MD, American Society for Gastrointestinal Endoscopy 0016-5107/\$36.00, <https://doi.org/10.1016/j.gie.2022.10.009>

Kommentar:

Katharina Zimmermann-Fraedrich and Prof. Dr. Thomas Rösch, Hamburg, 15.02.2023

Artificial intelligence and the push for small adenomas – all we need ?

Artificial Intelligence (AI) has been enthusiastically welcomed by the endoscopic community. However, most of the many potential applications have remained in the in vitro environment: That means that AI software has been developed and tested on images or videos only. However, polyp detection software by various companies has entered the field of clinical application and has been studied extensively in randomized trials. At the time of writing of this editorial, 19 such randomized trials are available as full publications¹⁻¹⁹. They all show a more or less significant increase in detection of small adenomas. Since this seems to be difficult to understand, the same results are summarized over and over again in no less than 16 meta analyses²⁰⁻³⁵ plus a protocol for another one³⁶, plus, of course, a meta analysis of some of these meta analyses³⁷.

Is the paper appearing in this issue of the journal using the Medtronic AI system³⁸ (ref) just another randomized trial ? The authors stress in the abstract that the topic „has had limited clinical evaluation“ which may not be entirely true (see above). The present study is distinct from most other randomized trials in several aspects: Here, the patient population was homogeneous, including only colonoscopies from a FIT-based screening programme. Furthermore, a cap, mostly Endocuff vision, was used at the discretion of the endoscopist. Endocuff per se has been shown to increase polyp yield in again more than 20 meta analyses³⁹, and lately also in a FIT-based randomized screening colonoscopy study in this journal⁴⁰. Caps were used in about 70% of colonoscopies, and

we wish that this would have been standardized. Finally, polyp and not adenoma detection rate was used as the main outcome parameter in contrast to almost all other studies.

The results show that polyp detection rate was slightly higher in the AI group at 85.7% compared with the control group at 79.7% ($p=0.05$). So basically, almost everybody had a polyp and more than 2/3 had an adenoma. No difference in adenoma detection rate (ADR) was found, but the level was already high in the control group. In other FIT-based screening programmes, ADR was as high as in this study's control group in the Netherlands 41 and lower in studies from other countries, namely 55% in Spain 42, 51% in Sweden , and 41% in Italy 40. In primary screening colonoscopy, ADR is naturally lower, since not preselected by a stool test: In the recently published NordICC trial ADR was 31% 43, similar to the German screening colonoscopy setting 44. A recent review looked into ADR differences in the control groups in randomized trials and found generally a very wide variation. The overall mean value of 37.5% was however increased by a factor of 1.6 within FIT-based screening programmes 45.

Case number calculation in the present study reads a bit strange („this study was powered to detect a 10% increase in polyp detection, from a detect rate of 20% in the control group up to 30% in the CADe group“), since in reality, polyp rate was almost 80% in the control group. Also, higher adenoma and polyp detection rates have been published in FIT-based screening colonoscopy programmes as outlined above. So, in essence, the study could have been underpowered, and with larger case numbers, an ADR increase from 65% to 71% could have been significant (if relevant is another question). Interestingly enough, numerical differences in adenomas were in the group < 5 mm (from 765 to 846) but also in the group > 1 cm (from 94 to 120 polyps), in some contradiction to most previous studies only showing small polyps to be found more frequently by AI, but this may be coincidental.

So, what can we conclude about clinical relevance of AI increasing ADR ? The first question is, do we see an upper limit of ADR which cannot be substantially improved any more by AI or other means – and therefore, may this study have reached the possible ADR ceiling. Looking at the RCTs mentioned above, the relative increase in ADR was dependent on the basic ADR level in the control group in most of the papers: Relative ADR increases were around 50% in low ADR papers 15, 18, about 30% in trials with ADR levels between 20-30% 11, 17, and 20-25% in studies with basic ADRE levels of 30-45% 8, 10, 14, such as in FIT-based screening programmes 2. This is somewhat logical - that there is less room for improvement in high ADR performers. We are confident that this will be the topic of another meta analysis soon. Tandem studies in AI showed an even greater effect on the adenoma

miss rate, but it is well known that tandem trials yield better results than comparative randomized studies 46.

The second question is, of course, the ultimate clinical relevance of increasing ADR from high to even higher levels. We know that ADR correlates with interval cancer rate, i.e. higher ADR prevents colorectal cancer better. However, we still do not know whether we have a cut-off ADR level, above which there is no or not much further improvement in cancer prevention. This was indirectly suggested by the Polish and Austrian follow-up studies 47, 48, which primarily took a cut-off level of 20% for their data analyses. In contrast, the Californian group suggested a linear correlation in their studies 49, 50. Their recent publication however includes figures which somehow contradict the conclusions 50. It appears logical, that if more than 2/3 of scoped persons have a (mostly small/very small) adenoma, then the risk factor ADR may of be less importance and finding more and more small adenomas may not be the key to success.

The third question is which adenomas should we chase and what else needs to be done. The relevance of small adenomas has been doubted by many database analyses in the last 10 years which correlated patients' prognosis with the stage of adenomas found and removed during colonoscopy, again confirmed in a large review at the end of last year 51. Another recent meta analysis summarized the evidence of 12 such studies 52; The authors uniformly showed no relevant disadvantage with regards to colorectal cancer development for persons with small adenomas only, as compared to the normal population or people with a normal colonoscopy. The worrisome finding of all these studies however is that the colorectal cancer incidence was 4fold higher when patients had advanced adenomas which were obviously removed: Should these patients not benefit much more from colonoscopy and polypectomy and perhaps brought back to the normal risk level? So, we presume, that there is more to colonoscopy quality and cancer prevention than just finding more and more small adenomas. We know that resection can be incomplete with sometimes worrisome rates 53-55, and so may be adherence to follow-up: Mostly, patients with small adenomas tend to be oversurveilled, those with advanced lesions undersurveilled 56-58 (and perhaps primarily underresected) . May we have the wrong focus here staring at ADR all the time?

Finally, randomized trials, as high evidence they may provide, also may have shortcomings; the focus of a study and the willingness to produce good results and to achieve a better publication may increase the examiners awareness and attention in both groups (Hawthorne effect), but perhaps more in the study group, here for AI. On the other hand, there are recent sobering reports about what happens if AI systems are incorporated into a colonoscopy programme: Papers have shown that

ADR did not increase in an US center 59, or even decreased in an Israeli hospital 60, perhaps due to shorter withdrawal times. The group from Würzburg showed by eyetracking that trainees focus their eyes in the middle of the picture when using AI, while without AI, they tended to look around more 61. This phenomenon is known from radiology and called „deskilling“. This may not be the intention of AI, which – as we can conclude – is still dependent on the examiners ability to maneuver the scope adequately and also to pay attention. If AI is expected to do the job, attention may be less

What do we need ? Studies should look at more relevant outcomes than just whether we find more small polyps (we already have abundant evidence that this is the case). Authors and editors should refrain from writing and accepting more and more meta analyses about AI polyp detection. And there are also more challenging applications to be studied, starting with tissue diagnosis (and histology replacement which may face quite a few legal and credentialing hurdles), but also performance, interpretation, documentation, risk stratification and follow-up of colonoscopies and patients with more advanced polyps, all parameters which have to be documented before, during and after colonoscopy. If some of this documentation paperwork is taken off our shoulders, we could perhaps better focus on good patient care and finally als on good clinical research.

References see supplementary appendix

1. Li MD, Huang ZR, Shan QY, et al. Performance and comparison of artificial intelligence and human experts in the detection and classification of colonic polyps. *BMC Gastroenterol* 2022;22:517.
2. Rondonotti E, Di Paolo D, Rizzotto ER, et al. Efficacy of a computer-aided detection system in a fecal immunochemical test-based organized colorectal cancer screening program: a randomized controlled trial (AIFIT study). *Endoscopy* 2022;54:1171-1179.
3. Gimeno-García AZ, Negrin DH, Hernández A, et al. Usefulness of a novel computer-aided detection system for colorectal neoplasia: A randomized controlled trial. *Gastrointest Endosc* 2022.
4. Xu H, Tang RSY, Lam TYT, et al. Artificial Intelligence-Assisted Colonoscopy for Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial. *Clin Gastroenterol Hepatol* 2022.
5. Yao L, Zhang L, Liu J, et al. Effect of an artificial intelligence-based quality improvement system on efficacy of a computer-aided detection system in colonoscopy: a four-group parallel study. *Endoscopy* 2022;54:757-768.
6. Wallace MB, Sharma P, Bhandari P, et al. Impact of Artificial Intelligence on Miss Rate of Colorectal Neoplasia. *Gastroenterology* 2022;163:295-304.e5.

7. Glissen Brown JR, Mansour NM, Wang P, et al. Deep Learning Computer-aided Polyp Detection Reduces Adenoma Miss Rate: A United States Multi-center Randomized Tandem Colonoscopy Study (CADET-CS Trial). *Clin Gastroenterol Hepatol* 2022;20:1499-1507.e4.
8. Xu L, He X, Zhou J, et al. Artificial intelligence-assisted colonoscopy: A prospective, multicenter, randomized controlled trial of polyp detection. *Cancer Med* 2021;10:7184-7193.
9. Kamba S, Tamai N, Saitoh I, et al. Reducing adenoma miss rate of colonoscopy assisted by artificial intelligence: a multicenter randomized controlled trial. *J Gastroenterol* 2021;56:746-757.
10. Repici A, Spadaccini M, Antonelli G, et al. Artificial intelligence and colonoscopy experience: lessons from two randomised trials. *Gut* 2022;71:757-765.
11. Liu P, Wang P, Glissen Brown JR, et al. The single-monitor trial: an embedded CAde system increased adenoma detection during colonoscopy: a prospective randomized study. *Therap Adv Gastroenterol* 2020;13:1756284820979165.
12. Luo Y, Zhang Y, Liu M, et al. Artificial Intelligence-Assisted Colonoscopy for Detection of Colon Polyps: a Prospective, Randomized Cohort Study. *J Gastrointest Surg* 2021;25:2011-2018.
13. Wang P, Liu P, Glissen Brown JR, et al. Lower Adenoma Miss Rate of Computer-Aided Detection-Assisted Colonoscopy vs Routine White-Light Colonoscopy in a Prospective Tandem Study. *Gastroenterology* 2020;159:1252-1261.e5.
14. Repici A, Badalamenti M, Maselli R, et al. Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial. *Gastroenterology* 2020;159:512-520.e7.
15. Gong D, Wu L, Zhang J, et al. Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study. *Lancet Gastroenterol Hepatol* 2020;5:352-361.
16. Wang P, Liu X, Berzin TM, et al. Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADE-DB trial): a double-blind randomised study. *Lancet Gastroenterol Hepatol* 2020;5:343-351.
17. Liu WN, Zhang YY, Bian XQ, et al. Study on detection rate of polyps and adenomas in artificial-intelligence-aided colonoscopy. *Saudi J Gastroenterol* 2020;26:13-19.
18. Su JR, Li Z, Shao XJ, et al. Impact of a real-time automatic quality control system on colorectal polyp and adenoma detection: a prospective randomized controlled study (with videos). *Gastrointest Endosc* 2020;91:415-424.e4.
19. Wang P, Berzin TM, Glissen Brown JR, et al. Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study. *Gut* 2019;68:1813-1819.

20. Ashat M, Klair JS, Singh D, et al. Impact of real-time use of artificial intelligence in improving adenoma detection during colonoscopy: A systematic review and meta-analysis. *Endosc Int Open* 2021;9:E513-e521.
21. Aziz M, Fatima R, Dong C, et al. The impact of deep convolutional neural network-based artificial intelligence on colonoscopy outcomes: A systematic review with meta-analysis. *J Gastroenterol Hepatol* 2020;35:1676-1683.
22. Aziz M, Haghbin H, Sayeh W, et al. Comparison of Artificial Intelligence With Other Interventions to Improve Adenoma Detection Rate for Colonoscopy: A Network Meta-analysis. *J Clin Gastroenterol* 2022.
23. Barua I, Vinsard DG, Jodal HC, et al. Artificial intelligence for polyp detection during colonoscopy: a systematic review and meta-analysis. *Endoscopy* 2021;53:277-284.
24. Deliwala SS, Hamid K, Barbarawi M, et al. Artificial intelligence (AI) real-time detection vs. routine colonoscopy for colorectal neoplasia: a meta-analysis and trial sequential analysis. *Int J Colorectal Dis* 2021;36:2291-2303.
25. Hassan C, Spadaccini M, Iannone A, et al. Performance of artificial intelligence in colonoscopy for adenoma and polyp detection: a systematic review and meta-analysis. *Gastrointest Endosc* 2021;93:77-85.e6.
26. Huang D, Shen J, Hong J, et al. Effect of artificial intelligence-aided colonoscopy for adenoma and polyp detection: a meta-analysis of randomized clinical trials. *Int J Colorectal Dis* 2021.
27. Li J, Lu J, Yan J, et al. Artificial intelligence can increase the detection rate of colorectal polyps and adenomas: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2020.
28. Lui TKL, Guo CG, Leung WK. Accuracy of artificial intelligence on histology prediction and detection of colorectal polyps: a systematic review and meta-analysis. *Gastrointest Endosc* 2020;92:11-22.e6.
29. Mori Y, Wang P, Løberg M, et al. Impact of Artificial Intelligence on Colonoscopy Surveillance After Polyp Removal: A Pooled Analysis of Randomized Trials. *Clin Gastroenterol Hepatol* 2022.
30. Nazarian S, Glover B, Ashrafian H, et al. Diagnostic Accuracy of Artificial Intelligence and Computer-Aided Diagnosis for the Detection and Characterization of Colorectal Polyps: Systematic Review and Meta-analysis. *J Med Internet Res* 2021;23:e27370.
31. Shah S, Park N, Chehade NEH, et al. Effect of computer-aided colonoscopy on adenoma miss rates and polyp detection: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2022.
32. Sivananthan A, Nazarian S, Ayaru L, et al. Does computer-aided diagnostic endoscopy improve the detection of commonly missed polyps? A meta-analysis. *Clin Endosc* 2022;55:355-364.

33. Spadaccini M, Iannone A, Maselli R, et al. Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis. *Lancet Gastroenterol Hepatol* 2021;6:793-802.
34. Xu Y, Ding W, Wang Y, et al. Comparison of diagnostic performance between convolutional neural networks and human endoscopists for diagnosis of colorectal polyp: A systematic review and meta-analysis. *PLoS One* 2021;16:e0246892.
35. Zhang Y, Zhang X, Wu Q, et al. Artificial Intelligence-Aided Colonoscopy for Polyp Detection: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *J Laparoendosc Adv Surg Tech A* 2021;31:1143-1149.
36. Shao L, Yan X, Liu C, et al. Effects of ai-assisted colonoscopy on adenoma miss rate/adenoma detection rate: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)* 2022;101:e31945.
37. Pan H, Cai M, Liao Q, et al. Artificial Intelligence-Aid Colonoscopy Vs. Conventional Colonoscopy for Polyp and Adenoma Detection: A Systematic Review of 7 Discordant Meta-Analyses. *Front Med (Lausanne)* 2021;8:775604.
38. Abe S, Oda I, Shimazu T, et al. Depth-predicting score for differentiated early gastric cancer. *Gastric Cancer* 2011;14:35-40.
39. Walls M, Houwen B, Rice S, et al. The effect of the endoscopic device Endocuff™/Endocuff vision™ on quality standards in colonoscopy: A systematic review and meta-analysis of randomized trials. *Colorectal Dis* 2022.
40. Zorzi M, Hassan C, Battagello J, et al. Adenoma detection by Endocuff-assisted versus standard colonoscopy in an organized screening program: the "ItaVision" randomized controlled trial. *Endoscopy* 2022;54:138-147.
41. Wisse PHA, Erler NS, de Boer SY, et al. Adenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test-Based Screening : A Population-Based Cohort Study. *Ann Intern Med* 2022;175:1366-1373.
42. Cubiella J, Castells A, Andreu M, et al. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs. *United European Gastroenterol J* 2017;5:255-260.
43. Bretthauer M, Løberg M, Wieszczy P, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. *N Engl J Med* 2022;387:1547-1556.
44. Brenner H, Altenhofen L, Kretschmann J, et al. Trends in Adenoma Detection Rates During the First 10 y of the German Screening Colonoscopy Program. *Gastroenterology* 2015.
45. Hassan C, Piovani D, Spadaccini M, et al. Variability in Adenoma Detection Rate in Control Groups of Randomized Colonoscopy Trials. *Gastrointest Endosc* 2022.

46. Zimmermann-Fraedrich K, Pohl H, Rösch T, et al. Designs of colonoscopic adenoma detection trials: more positive results with tandem than with parallel studies - an analysis of studies on imaging techniques and mechanical devices. *Gut* 2020.
47. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. *N Engl J Med* 2010;362:1795-803.
48. Waldmann E, Penz D, Šinkovec H, et al. Interval cancer after colonoscopy in the Austrian National Screening Programme: influence of physician and patient factors. *Gut* 2020.
49. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med* 2014;370:1298-306.
50. Schottinger JE, Jensen CD, Ghai NR, et al. Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer. *Jama* 2022;327:2114-2122.
51. Baile-Maxía S, Mangas-Sanjuán C, Ladabaum U, et al. RISK FACTORS FOR METACHRONOUS COLORECTAL CANCER OR ADVANCED ADENOMAS AFTER ENDOSCOPIC RESECTION OF HIGH-RISK ADENOMAS. *Clin Gastroenterol Hepatol* 2022.
52. Duvvuri A, Chandrasekar VT, Srinivasan S, et al. Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis. *Gastroenterology* 2021;160:1986-1996.e3.
53. Pohl H, Anderson JC, Aguilera-Fish A, et al. Recurrence of Colorectal Neoplastic Polyps After Incomplete Resection. *Ann Intern Med* 2021;174:1377-1384.
54. Djinbachian R, Iratni R, Durand M, et al. Rates of Incomplete Resection of 1- to 20-mm Colorectal Polyps: A Systematic Review and Meta-Analysis. *Gastroenterology* 2020;159:904-914.e12.
55. Rotermund C, Djinbachian R, Taghiakbari M, et al. Recurrence rates after endoscopic resection of large colorectal polyps: A systematic review and meta-analysis. *World J Gastroenterol* 2022;28:4007-4018.
56. Schoen RE, Pinsky PF, Weissfeld JL, et al. Utilization of surveillance colonoscopy in community practice. *Gastroenterology* 2010;138:73-81.
57. Murphy CC, Sandler RS, Grubber JM, et al. Underuse and Overuse of Colonoscopy for Repeat Screening and Surveillance in the Veterans Health Administration. *Clin Gastroenterol Hepatol* 2016;14:436-444.e1.
58. Schwarz S, Schäfer W, Horenkamp-Sonntag D, et al. Follow-up of 3 Million Persons Undergoing Colonoscopy in Germany: Utilization of Repeat Colonoscopies and Polypectomies Within 10 Years. *Clin Transl Gastroenterol* 2020;12:e00279.
59. Ladabaum U, Shepard J, Weng Y, et al. Computer-aided detection of polyps does not improve colonoscopist performance in a pragmatic implementation trial. *Gastroenterology* 2022.



60. Levy I, Bruckmayer L, Klang E, et al. Artificial Intelligence-Aided Colonoscopy Does Not Increase Adenoma Detection Rate in Routine Clinical Practice. *Am J Gastroenterol* 2022;117:1871-1873.
61. Troya J, Fitting D, Brand M, et al. The influence of computer-aided polyp detection systems on reaction time for polyp detection and eye gaze. *Endoscopy* 2022;54:1009-1014.